Clinical trial
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
NCT00022529 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00022529 |
|---|---|
| Title | BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of Intravenous BMS-214662 FTI (NSC# 710086) and Herceptin (NSC# 688097) Weekly in Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | BMS-214662, trastuzumab, pharmacological study |
| Enrollment | 28 |
| Start date | Jul 1, 2001 |
| Primary completion | Jan 1, 2004 |
| First posted | Jun 17, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: